Xarelto trial results reaffirmed despite faulty device

FRANKFURT (Reuters) - Europe's drug regulator said on Friday the defective blood clotting test device used in a key trial for the approval of Bayer's top-selling anti-clotting drug Xarelto did not distort the study's main findings.

http://ift.tt/xePdMM

from Reuters: Health News
via animenewspro